Compare Bristol-Myers Squibb Co (BMY) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Main Street Capital Corporation — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Main Street Capital Corporation trades at $53.19 (market cap $4.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 23.5× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays the higher dividend (8.25%). Which is the better fit depends on your goals.
| BMY | MAIN | |
|---|---|---|
Market Cap | $116.30B | $4.94B |
Sector | Health | Financials |
52-Week High | $62.37 | $67.54 |
52-Week Low | $42.60 | $49.63 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | 8.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Main Street Capital (MAIN) trades at $52.51, down 0.62% on the day, with a bullish technical signal from moving averages. The company reported a net income margin of 81.08% for 2025, though revenue dipped to $592M from $601M in 2024. Recent news highlights MAIN's premium valuation among internally managed BDCs and a consistent dividend history, with the latest quarterly earnings showing a mix of beats and misses against expectations.
The outlook is supported by a consensus price target of $57.75, implying upside, but risks include softening earnings and negative operating cash flow. The stock offers a high yield, but investors should weigh the sustainability of dividends against rising expenses and a higher share count noted in recent analysis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
